Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

Izumi, Kouji; Mizokami, Atsushi; Namiki, Mikio; Inoue, Shogo; Tanaka, Nobumichi; Yoshio, Yuko; Ishibashi, Kei; Kamiyama, Manabu; Kawai, Noriyasu; Enokida, Hideki; Shima, Takashi; Takahara, Shizuko

doi:10.1186/s12885-017-3661-2

Article metrics
Last updated: Thu, 25 Apr 2024 9:59:38 Z

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

Access & Citations

8152

Article Accesses
11

Web of Science
15

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.